Press

Phillips Lytle Launches Psychedelic & Mental Health Therapies Practice

Aug 19 • 5 min read

Phillips Lytle LLP announced the launch of its Psychedelics & Mental Health Therapies Practice Team, which is uniquely equipped to help pharmaceutical companies, research organizations and other stakeholders navigate the evolving legal and regulatory landscape related to the development, approval and use of psychedelic medications. Phillips Lytle Special Counsel Kyle W. Mack, who holds a doctorate in pharmacy,…

Universal Ibogaine Provides Update on Kelburn Recovery Center

Aug 19 • 3 min read

Universal Ibogaine Inc. (TSXV: IBO | OTC: IBOGF) is a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care. Ibogaine is a plant derived medicine used in addiction treatment and has been shown to deliver detoxification from opioids, heroin and other substances, and can provide a several month window free of drug cravings….

Reunion Neuroscience Inc. Commenced Trading on the Toronto Stock Exchange August 17, 2022

Aug 18 • 2 min read

Reunion Neuroscience Inc., a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange under the ticker symbol “REUN” at the opening of the market on August 17, 2022. Trading of the…

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Aug 18 • 3 min read

PharmAla Biotech (CSE: MDMA) has achieved a historic milestone: it is currently the only publicly-traded company to have produced GMP MDMA at scale. The company believes that it is currently the only source for commercially-available GMP MDMA other than the Multidisciplinary Association for Psychedelic Studies (MAPS). With the release of this large-scale batch of LaNeo™ MDMA…

Core One Labs: Vocan Successfully Converts Psilocin Precursor into Psilocybin

Aug 17 • 2 min read

Further to its press release dated August 12, 2022, Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6 | WKN: A3CSSU) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. has successfully employed enzymatic production methods to convert a chemically produced psilocin developed by the Company’s recently acquired Awakened Biosciences Inc.’s, into…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441